Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-25 @ 2:16 AM
NCT ID:
NCT06335160
Eligibility Criteria:
Inclusion Criteria:
* Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Exclusion Criteria:
* \- Patients with severe UC
* Significant liver and kidney function abnormalities
* Diabetic patients
* Patients with Colorectal cancer patients
* Patients taking rectal or systemic steroids
* Patients on immunosuppressants or biological therapies
* Addiction to alcohol and / or drugs
* Known allergy to the studied medications
* History of complete or partial colectomy.
* Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction).
* Patients with other inflammatory diseases and active infection.
* Patients with stressful condition (COPD, morbid obesity).
* Patients with liver disease.
* Patients with thrombocytopenia and neutropenia.
* Patients with any type of seizures (case report for mebendazole induced convulsion).
* Patients with renal disease (case report for mebendazole induced nephrotoxicity).
* Patients with coagulation disorders.
* Patients on metronidazole (to avoid Stevens-Johnson syndrome).
* Patients with hypersensitivity to mebendazole, albendazole or benzimidazole
* Patients using antioxidants.
* Pregnant and lactating females.
* Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT06335160
Study Brief:
Protocol Section:
NCT06335160